TNDM · Tandem Diabetes Care Inc · Documents

Mar 15

Current report 8-K Events of Mar 11

Director or officer change, or executive pay

Feb 22

Earnings call

Q4 2021 earnings call

Feb 22

Current report 8-K Events of Feb 3

Financial results, Director or officer change, or executive pay

Feb 22

Annual report 10-K FY2021, ended Dec 31

Annual report for FY2021

Revenue $702.8M ▲ 40.9% Net income $15.57M Diluted EPS $0.24

Feb 16

Current report 8-K

Other events

Nov 3

Earnings call

Q3 2021 earnings call

Nov 3

Current report 8-K

Financial results

Nov 3

Quarterly report 10-Q FY2021 Q3, ended Sep 30

Quarterly report for FY2021 Q3

Revenue $179.63M ▲ 45.3% Net income $5.79M Diluted EPS $0.09

Sep 17

Current report 8-K Events of Sep 15

Entered into a material agreement

Aug 4

Earnings call

Q2 2021 earnings call

Aug 4

Current report 8-K

Financial results

Aug 4

Quarterly report 10-Q FY2021 Q2, ended Jun 30

Quarterly report for FY2021 Q2

Revenue $172.14M ▲ 57.6% Net income $4.01M Diluted EPS $0.06

May 19

Current report 8-K Events of May 18

Shareholder vote results

May 5

Earnings call

Q1 2021 earnings call

May 5

Current report 8-K

Financial results

May 5

Quarterly report 10-Q FY2021 Q1, ended Mar 31

Quarterly report for FY2021 Q1

Revenue $141.04M ▲ 44.0% Net loss $5.04M

Apr 7

Proxy statement DEF 14A

Proxy statement

Apr 7

Proxy statement DEFA14A

Proxy statement

Feb 24

Earnings call

Q4 2020 earnings call

Feb 24

Current report 8-K Events of Feb 23

Financial results, Director or officer change, or executive pay

Feb 24

Annual report 10-K FY2020, ended Dec 31

Annual report for FY2020

Revenue $498.83M ▲ 37.7% Net loss $34.38M

Feb 8

Current report 8-K Events of Feb 4

Charter or bylaw amendment, or fiscal year change

Dec 14

Current report 8-K Events of Dec 11

Director or officer change, or executive pay

Nov 23

Current report 8-K Events of Nov 20

Entered into a material agreement

Nov 5

Earnings call

Q3 2020 earnings call

Nov 5

Current report 8-K

Financial results

Nov 5

Quarterly report 10-Q FY2020 Q3, ended Sep 30

Quarterly report for FY2020 Q3

Revenue $123.6M ▲ 30.6% Net loss $9.41M Diluted EPS -$0.15

Aug 21

Current report 8-K Events of Aug 19

Charter or bylaw amendment, or fiscal year change

Jul 30

Earnings call

Q2 2020 earnings call

Jul 30

Current report 8-K

Financial results

Jul 30

Current report 8-K Events of Jul 29

Director or officer change, or executive pay

Jul 30

Quarterly report 10-Q FY2020 Q2, ended Jun 30

Quarterly report for FY2020 Q2

Revenue $109.24M ▲ 17.1% Net loss $27.11M

Jul 1

Current report 8-K

Other events

Jun 25

Current report 8-K Events of Jun 24

Regulation FD disclosure

Jun 18

Current report 8-K Events of Jun 16

Other events

Jun 5

Current report 8-K Events of Jun 4

Director or officer change, or executive pay

May 28

Current report 8-K Events of May 27

Other events

May 27

Current report 8-K Events of May 26

Director or officer change, or executive pay

May 26

Proxy statement DEFA14A

Proxy statement

May 18

Proxy statement DEFA14A

Proxy statement

May 15

Current report 8-K Events of May 12

Entered into a material agreement, New debt or off-balance-sheet obligation, Unregistered sale of equity

Apr 30

Earnings call

Q1 2020 earnings call

Apr 30

Current report 8-K

Financial results

Apr 30

Quarterly report 10-Q FY2020 Q1, ended Mar 31

Quarterly report for FY2020 Q1

Revenue $97.93M ▲ 48.4% Net loss $14.87M

Apr 15

Proxy statement DEF 14A

Proxy statement

Apr 15

Proxy statement DEFA14A

Proxy statement

Feb 24

Current report 8-K

Financial results, Director or officer change, or executive pay

Feb 24

Annual report 10-K FY2019, ended Dec 31

Annual report for FY2019

Revenue $362.31M ▲ 97.0% Net loss $24.75M